Ipinzan (Metformin Hydrochloride, Vildagliptin)

Metformin Hydrochloride lowers hepatic glucose production and increases insulin sensitivity in muscle and fat tissue. Vildagliptin blocks the DPP‑4 enzyme, which prolongs the activity of incretin hormones that stimulate insulin release only when blood glucose is elevated. Together they reduce both fasting and post‑prandial glucose.

The specific dose of Ipinzan is determined by the prescribing healthcare professional based on the patient’s renal function, glycaemic targets, and concomitant therapies. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

Safety of Ipinzan in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To request Ipinzan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ipinzan combines a biguanide (metformin) with a DPP‑4 inhibitor (vildagliptin), offering dual mechanisms that improve insulin sensitivity and enhance glucose‑dependent insulin secretion. Compared with metformin alone, it provides greater post‑prandial glucose reduction, and unlike sulfonylureas, it carries a lower risk of hypoglycaemia when used as monotherapy.

Ipinzan tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Ipinzan is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and not crush or split the tablets unless specifically instructed.

The most serious adverse events include lactic acidosis (primarily linked to metformin) and severe hypoglycaemia when combined with other glucose‑lowering agents. Rare but critical reactions such as acute pancreatitis, anaphylaxis, and significant hepatic dysfunction may also occur and require immediate medical attention.

Ipinzan is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, and those with a history of lactic acidosis. Caution is advised for individuals with hepatic disease, uncontrolled heart failure, or who are pregnant without clear benefit.